by Genna Contino | Dec 5, 2024
As pharmaceutical giant Eli Lilly evolves its popular obesity and diabetes drug, the company has discovered positive side effects that could develop into spin-off medications. Users of GLP-1 drugs, which regulate blood sugar, appetite and digestion, have reported...
by Joseph Lingad | Sep 25, 2023
All year health insurance stocks have been under the weather, battling against uncertainties, but the long-term fundamentals should rejuvenate the well-being of insurers’ core business in due course. The bellwether of all the healthcare payers is UnitedHealth...
by Suzannah Cavanaugh | Oct 25, 2020
Walgreens Boots Alliance, Inc. reported dismal fourth-quarter earnings that managed to exceed low-ball estimates. Shares surged in response to surpassed expectations. Walgreens reported adjusted earnings per share (EPS) of $1.02, down 28.2% from the same period last...
